| Literature DB >> 27237579 |
Zhenghua Hou1, Wenhao Jiang1, Yingying Yin1, Zhijun Zhang2, Yonggui Yuan3.
Abstract
Depression is the most disabling disorder worldwide that accounts for the highest proportion of global burden attributable to mental disorders. Major depressive disorder (MDD) is characterized by deep sadness, reduced energy, vegetative nervous system dysregulation, cognitive dysfunction, and even a high suicidal tendency. Although other treatment choices are available, antidepressant medication is the front-line treatment option for MDD. Regarding clinical efficacy, only ~50% of patients respond to frontline antidepressants, and <33% obtain remission. Currently, objective indexes to guide clinical decisions are still lacking. Furthermore, knowledge about the neurobiological mechanisms underlying discrepant antidepressant outcomes is still also fragmentary. In the present review, we discuss the current research progress and clinical opinions on MDD in China.Entities:
Keywords: Antidepressant; Biomarker; China; Epidemiology; Major depressive disorder; Pathogenesis
Mesh:
Year: 2016 PMID: 27237579 PMCID: PMC5563780 DOI: 10.1007/s12264-016-0037-6
Source DB: PubMed Journal: Neurosci Bull ISSN: 1995-8218 Impact factor: 5.203